BOSTON-BASED VALO HEALTH, WHICH ANALYZES CLINICAL DATA TO IDENTIFY MOLECULES AND PREDICT THEIR CHANCES FOR USE IN DRUGS, RAISES $300M SERIES B (DANIEL MCCOY/WICHITA BUSINESS JOURNAL)

-

Boston-based Valo Health, which analyzes clinical data to identify molecules and predict their chances for use in drugs, raises $300M Series B  —  A Boston-based company working to improve the way drugs are brought to the market has secured $110 million in Series B funding from Koch Disruptive Technologies.

Source

Related Post